Abstract
β-Escin, a natural triterpene saponin was extracted from Aesculus hippocastanum seeds, which have been widely used to treat inflammation in traditional medicine. In an effort to study the possible anti-tumor effects of β-escin, we performed wound healing, invasion, and adhesion assays to examine the effects of β-escin on cell migration, invasion, and angiogenesis. Our results revealed that β-escin inhibits cell migration as well as motility in B16F10 and SK-MEL5 cells in a dose-dependent manner. RT-PCR and Western blot analysis showed that β-escin increased TIMP-1, -2 while significantly downregulated phosphorylated extracellular signal-regulated kinase (p-ERK) expression, and suppressing nuclear factor-kappa B (NF-κB) and inhibitor of nuclear factor-kappa B (IκB) expression. Overall, the data from the current study suggest that β-escin has the potential for inhibiting both metastatic and angiogenic activities, and are the earliest evidence for the involvement of the NF-κB/IκB signaling in β-escin-induced anti-tumor effects.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1606-1610 |
| Number of pages | 5 |
| Journal | Biological and Pharmaceutical Bulletin |
| Volume | 41 |
| Issue number | 10 |
| DOIs | |
| State | Published - Jan 1 2018 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmaceutical Science
Cite this
}
Inhibition of migration and invasion in melanoma cells by β-escin via the ERK/NF-κB signaling pathway. / Kwak, Hyeong Seob; An, Hongyan; Alam, Md Badrul; Choi, Won Sik; Lee, Sang; Lee, Sang Han.
In: Biological and Pharmaceutical Bulletin, Vol. 41, No. 10, 01.01.2018, p. 1606-1610.Research output: Contribution to journal › Article
TY - JOUR
T1 - Inhibition of migration and invasion in melanoma cells by β-escin via the ERK/NF-κB signaling pathway
AU - Kwak, Hyeong Seob
AU - An, Hongyan
AU - Alam, Md Badrul
AU - Choi, Won Sik
AU - Lee, Sang
AU - Lee, Sang Han
PY - 2018/1/1
Y1 - 2018/1/1
N2 - β-Escin, a natural triterpene saponin was extracted from Aesculus hippocastanum seeds, which have been widely used to treat inflammation in traditional medicine. In an effort to study the possible anti-tumor effects of β-escin, we performed wound healing, invasion, and adhesion assays to examine the effects of β-escin on cell migration, invasion, and angiogenesis. Our results revealed that β-escin inhibits cell migration as well as motility in B16F10 and SK-MEL5 cells in a dose-dependent manner. RT-PCR and Western blot analysis showed that β-escin increased TIMP-1, -2 while significantly downregulated phosphorylated extracellular signal-regulated kinase (p-ERK) expression, and suppressing nuclear factor-kappa B (NF-κB) and inhibitor of nuclear factor-kappa B (IκB) expression. Overall, the data from the current study suggest that β-escin has the potential for inhibiting both metastatic and angiogenic activities, and are the earliest evidence for the involvement of the NF-κB/IκB signaling in β-escin-induced anti-tumor effects.
AB - β-Escin, a natural triterpene saponin was extracted from Aesculus hippocastanum seeds, which have been widely used to treat inflammation in traditional medicine. In an effort to study the possible anti-tumor effects of β-escin, we performed wound healing, invasion, and adhesion assays to examine the effects of β-escin on cell migration, invasion, and angiogenesis. Our results revealed that β-escin inhibits cell migration as well as motility in B16F10 and SK-MEL5 cells in a dose-dependent manner. RT-PCR and Western blot analysis showed that β-escin increased TIMP-1, -2 while significantly downregulated phosphorylated extracellular signal-regulated kinase (p-ERK) expression, and suppressing nuclear factor-kappa B (NF-κB) and inhibitor of nuclear factor-kappa B (IκB) expression. Overall, the data from the current study suggest that β-escin has the potential for inhibiting both metastatic and angiogenic activities, and are the earliest evidence for the involvement of the NF-κB/IκB signaling in β-escin-induced anti-tumor effects.
UR - http://www.scopus.com/inward/record.url?scp=85054250995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054250995&partnerID=8YFLogxK
U2 - 10.1248/bpb.b18-00251
DO - 10.1248/bpb.b18-00251
M3 - Article
C2 - 30270331
AN - SCOPUS:85054250995
VL - 41
SP - 1606
EP - 1610
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
SN - 0918-6158
IS - 10
ER -